1. |
Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood, 1990, 76 (9):1680-1697.
|
2. |
Skubas NJ, Gj D. Optimal management of bleeding complications after cardiac surgery. Semin Cardiothorac Vasc Anesth, 2001, 5 (3):217-228.
|
3. |
米勒. 米勒麻醉学. 北京:北京大学医学出版社, 1990-1992.
|
4. |
DeLaria GA, Tyner JJ, Hayes CL, et al. Heparin-protamine mismatch.A controllable factor in bleeding after open heart surgery. Arch Surg,1994, 129 (9):944-950.
|
5. |
Bull BS, Korpman RA, Huss WM, et al. Heparin therapy during extrac orporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg,.
|
6. |
Ghai J, Luzt C, Ramamuthy N, et al. Method for testing a multi-channel blood assay cartridge . 2011[2013-07-17] . http://www.google. com. hk/patents .
|
7. |
Akl BF, Vargas GM, Neal J, et al. Clinical experience with theactivated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass. J Thorac Cardiovasc Surg, 1980, 79 (1):97-102.
|
8. |
Jobes DR, Aitken GL, Shaffer GW. Increased accuracy and precisionof heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg, 1995, 110 (1):36-45.
|
9. |
Preiss DU, Schmidt-Bleibtreu H, Berguson P, et al. Blood transfusionrequirements in coronary artery surgery with and without the activatedclotting time (ACT) technique. Klin Wochenschr, 1985, 63 (6):252-256.
|
10. |
Gruenwald CE, Manlhiot C, Chan AK, et al. Randomized, controlledtrial of individualized heparin and protamine management in infants undergoing cardiac surgery with cardiopulmonary bypass. J Am Coll Cardiol, 2010, 56 (22):1794-1802.
|
11. |
唐佳丽, 李刚, 杜磊, 等. 鱼精蛋白个体化使用减少心脏直视手术后患者出血的研究. 中国胸心血管外科临床杂志, 2010, 17 (2):105-108.
|
12. |
Guo Y, Tang J, Du L, et al. Protamine dosage based on two titrationsreduces blood loss after valve replacement surgery:a prospective, double-blinded, randomized study. Can J Cardiol, 2012, 28 (5):547-552.
|
13. |
, 69 (5):674-684.
|